AnnJi Pharmaceutical Co., Ltd. is launching the first-in-patient study of AJ201 for the treatment of SBMA (Spinal and Bulbar Muscular Atrophy, or Kennedy’s Disease) to evaluate the safety and clinical responses of AJ201. This study will take place in six clinical sites across the United States and patient recruitment is expected to begin in late

Dr. Cheng-Lung (Andy) Chen presented a scientific poster in “2022 Annual Meeting of Taiwan Neurological Society” titled “A Phase 1, Randomized, Double Blind, Placebo Controlled Study, To Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of AJ201 in Healthy Volunteers”, in which pharmacological safety and pharmacokinetics (PK) of AJ201 in

AnnJi’s scientists published an Opinion in the International Journal of Dermatology and Clinical Research (IJDCR), in which AnnJi presented evidences that J9 and JM17 (the APIs of AJ101 and AJ201, respectively) enhance the degradation of androgen receptors and activate the antioxidant responses. AJ101 is a topical cream formulation being developed for the treatment of acne

To raise awareness of Kennedy’s Disease and to bring resources to support relevant research programs, AnnJi supported the international fundraising activities co-organized by the Kennedy’s Disease Association in the UK and the US, “The Great Road Trip” in early 2022. In the “Great Road Trip”, the donors and volunteers took turns driving a 40-year-old Citroen

AJ201 is a first-in-class pleiotropic small molecule under development by AnnJi for the treatment of Kennedy’s disease, a rare neurological disorder. Patient enrollment of a Phase 2a trial for AJ201 will be initiated in the US by the end of 2022. Dr. Tsung-Pin (Andrew) Pai presented a scientific poster in “2022 International Conference of Big

AnnJi is a clinical-stage pharmaceutical company focusing on developing innovative therapeutics to improve the quality of life of patients with dermatological and neurological diseases. Watch online (below or BIOAsia-Taiwan 2022 if you have registered for the conference), for the latest update of our clinical projects: AJ101 for dermatology and AJ201 for rare neurological diseases. We